Liposomal Amphotericin B

Liposomal Amphotericin B (20 mg/kg; daily administration) reduces renal fungal burden in a dose-dependent manner in a mouse Candida glabrata infection model, but combination with Caspofungin (HY-17006A) and Micafungin (HY-17579) is required to achieve complete pathogen clearance^[1].
Liposomal Amphotericin B (3-20 mg/kg; daily) exhibits dose-dependent efficacy in reducing brain fungal burden in a mouse model of cryptococcal meningitis, with the 20 mg/kg/day dose achieving the maximal reduction but failing to completely eliminate the fungi^[1].
Liposomal Amphotericin B (10 mg/kg; daily) prolongs the survival of diabetic mouse models with disseminated Rhizopus oryzae mucormycosis^[1].
Liposomal Amphotericin B (10 mg/kg; single dose; administered 7 days prior to challenge) completely prevents primary disseminated histoplasmosis in both immunocompetent and immunosuppressed mice, but the protective effect cannot be sustained long-term in immunosuppressed mice^[1].
Liposomal Amphotericin B (administered via nebulization, with three 1-hour intervals) prevents invasive pulmonary aspergillosis without systemic drug exposure^[1].
Liposomal Amphotericin B (administered via nebulization, 20 minutes per dose, 3 doses total) maintains sustained drug concentrations in the lungs of mice, thereby preventing pulmonary cryptococcosis in mice^[1].
Liposomal Amphotericin B (5 mg/kg; daily) induces dose-dependent improvements in lung weight, fungal density, infarction score, and galactomannan concentration in a rabbit model of invasive pulmonary aspergillosis^[1].
Liposomal Amphotericin B achieves complete sterilization of the brain in a rabbit model of Candida meningoencephalitis^[1].
Liposomal Amphotericin B (10 mg/mL; lock therapy; 8 hours daily for 7 consecutive days) completely eradicates Candida albicans biofilms on indwelling rabbit catheters^[1].
Liposomal Amphotericin B (0.8 mg/kg; single dose or 5-50 mg/kg; administered every other day; total 6 doses) achieves complete sterilization of the liver, spleen and lungs in a mouse model of visceral leishmaniasis after six administrations^[1].